Enhanced glycoselective bioaffinity proteins
![](/46/pdcnewsitem/03/77/67/amsbiopr156-image.jpg)
AMSBIO launches a range of recombinant prokaryotic lectins.
AMSBIO has introduced a range of Recombinant Prokaryotic Lectins (RPLs). RPLs are enhanced glycoselective bioaffinity proteins that enable efficient detection, analysis and selective isolation of glycosylated biomolecules.
RPLs offer many advantages over traditional plant and eukaryotic lectins. They also offer many advantages over current glycoanalytical and chromatographic methodologies that are not glycoselective or require prior release of glycans which results in the sample destruction.
Recombinant production methods present opportunities to manipulate RPL glycan binding properties through the use of site specific mutagenesis strategies. Lectins can be engineered to enhance their affinity for a given glycan moiety or to alter their specificity for alternative glycan moieties. This can allow RPL properties to be tailored for specific targets or to enhance their performance for specific applications.
RPLs exhibit excellent stability enabling RPL bioaffinity matrices to be reused many times. Because of their prokaryotic origins RPLs lack the presence of disulphide bonds. This allows RPLs to be used in the presence of reducing agents for applications under denaturing conditions.
In standard ELLA formats RPLs enable significantly greater sensitivity of detection at lower lectin concentrations than that required for plant lectins. RPLs exhibit greater selectivity and higher affinity for glycosylated targets than comparable plant and eukaryotic lectins. RPLs are expressed with genetically incorporated poly-histidine tags that enable simple one step and high capacity purification of products via immobilized metal affinity chromatography (IMAC).
Recombinant expression and selective affinity purification of RPLs results in the production of products of consistent high quality, purity and performance. This is in contrast to plant lectins for which variation in performance (from batch to batch and from one supplier to another) has traditionally been reported.
RPLs expression is readily scalable using Stirred Tank Reactor (STR) systems. This combined with the high capacity and scalability of IMAC purification enables cost effective production of RPLs in sufficient quantities required for large-scale applications in the separation and purification of glycosylated biomolecules.
Related News
-
News Ophthalmologic drug product Eylea faces biosimilar threats after FDA approvals
Regeneron Pharmaceutical’s blockbuster ophthalmology drug Eylea is facing biosimilar competition as the US FDA approves Biocon’s Yesafili and Samsung Bioepis/Biogen’s Opuviz. -
News ONO Pharmaceutical expands oncology portfolio with acquisition of Deciphera
ONO Pharmaceutical, out of Japan, is in the process of acquiring cancer-therapy maker Deciphera Pharmaceuticals for US$2.4 billion. -
News First offers for pharma from Medicare drug price negotiations
Ten high-cost drugs from various pharma manufacturers are in pricing negotiations in a first-ever for the US Medicare program. President Biden’s administration stated they have responded to the first round of offers. -
News Eli Lilly’s Zepbound makes leaps and bounds in weight-loss drug market
In the last week, Eli Lilly has announced their partnership with Amazon.com’s pharmacy unit to deliver prescriptions of Zepbound. Zepbound has also surpassed Novo Nordisk’s Wegovy for the number of prescriptions for the week of March 8.&nbs... -
News Chasing new frontiers at LEAP – The National Biotechnology Strategy Keynote
On the third day of LEAP (4–7 March 2024, Riyadh Exhibition and Convention Centre, Malham, Saudi Arabia) the CPHI Middle East team hosted the Future Pharma Forum, to set the scene for an exciting new event for the pharma community, coming to Riya... -
News Pfizer maps out plans for developing new oncology therapeutics by 2030
Pfizer dilvulges plans to investors around growing their cancer portfolio, and the drugs they will be focusing on developing after their aquisition of Seagen in 2023. -
News Generics threat to Merck’s Bridion as Hikma seeks pre-patent expiry approval
Merck has disclosed they received notice from Hikma Pharmaceuticals for seeking a pre-patent expiry US FDA approval for Hikma’s generic version of Merck’s Bridion. -
News Bernie Sanders vs Big Pharma - the latest on drug price negotiations
In a hearing in front of the US Senate, three of the biggest pharmaceutical companies in America are challenged over exorbitant prescription drug prices, with Sanders claiming their actions are limiting the population's access to affordable healthc...
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance